Ceribell EEG Analysis Software
Ceribell, Inc. · Decision date Sep 16, 2026
What did the FDA decide?
Ceribell, Inc. received a substantially equivalent (SESE) decision for its Ceribell EEG Analysis Software under 510(k) K261712, dated September 16, 2026, with the FDA public record listing a receipt date of May 22, 2026. The device is a Class II electroencephalograph under 21 CFR 882.1400, product codes OLT and OMA, in the neurology specialty. SESE is a clearance to market, not premarket approval.
The software is intended for review, monitoring and analysis of EEG recordings from scalp-electrode EEG devices, with quantitative measures including frequency band metrics and burst suppression, plus aEEG functionality; the summary states these measures should be interpreted with the original waveforms. The summary names encevis (K240993) as primary predicate and states the subject device claims a subset of functions, excluding automatic seizure or spike detection. The letter and summary give conflicting receipt dates, and the summary's predicate product codes differ from the public record; performance data are not described here.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Neurology
- Decision date
- Sep 16, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K261712
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Ceribell, Inc.
- Product code
- OLT
- Decision code
- SESE
- Decision date
- Sep 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Non-Normalizing Quantitative Electroencephalograph Software.
- Applicant
- Ceribell, Inc.
- Product code
- OLT
- FDA device class
- 2
FDA decision timeline
K261712 received
Application receipt date recorded by FDA.
K261712 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Ceribell, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Sunnyvale, CA
Sources and methodology
- Original FDA record: K261712
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records